Eisai Highlights New Research at 50th ASCO Annual Meeting
HATFIELD, England, May 15, 2014 /PRNewswire/ --
FOR EMEA MEDIA ONLY - NOT FOR SWISS JOURNALISTS
Data underscore breadth of oncology portfolio
Eisai announced today that 16 abstracts highlighting new study results will be presented during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from 30 May to 3 June, 2014.
"Anchored by our human health care mission, Eisai's commitment to people with cancer and their families is evidenced by our focus on sometimes overlooked patient populations, and our investment in the development of innovative treatment options that have the potential to impact these communities. Oncology is a key franchise area for our company with a diverse portfolio of treatments and supportive care agents. The studies being presented at this year's ASCO Annual Meeting reflect our hhc mission and commitment to providing options for people with cancer in need, whether those needs affect a few or many," said Kenichi Nomoto, Ph.D., President, Oncology Product Creation Unit at Eisai Inc.
Of note, the results of a Phase III study with lenvatinib, an investigational agent being evaluated for the treatment for radioiodine-refractory differentiated thyroid cancer (RR-DTC), will be included in the ASCO press conference on Saturday 31 May. The data will also be presented on Monday 2 June, 2014.
Additional presentations will include results from the continued study of Halaven® (eribulin) for investigational uses in both early and late-stage breast cancer.
The following Eisai abstracts are accepted for presentation at this year's ASCO meeting:
Product Abstract Name
Lenvatinib
A phase III, multicenter, double-blind,
(E7080) placebo-controlled trial of lenvatinib (E7080) in
patients with 131I-refractory differentiated thyroid
Abstract No: cancer (SELECT).
LBA6008 Oral Presentation
Lenvatinib Prognostic and predictive role of circulating
angiopoietin-2 in multiple solid tumors: An analysis of
(E7080) approximately 500 patients treated with lenvatinib
across tumor types.
Abstract No:
11061 Poster Presentation
Lenvatinib A multicenter, open-label, phase 3 trial to compare the
efficacy and safety of lenvatinib (E7080) versus
(E7080) sorafenib in first-line treatment of subjects with
unresectable hepatocellular carcinoma.
Abstract No:
TPS4153 Poster Presentation
Lenvatinib E7080 (Lenvatinib) in Addition to Best Supportive Care
(BSC) versus BSC Alone in Third Line or Greater
(E7080) Non-Squamous, Non Small Cell Lung Cancer (NSCLC)
Abstract No: 8043 Poster Presentation
Pharmokinetics (PK) of eribulin mesylate in cancer
Eribulin patients with normal and impaired renal function.
Abstract No: 2595 Poster Presentation
Efficacy of eribulin in patients with metastatic breast
Eribulin cancer (MBC): a pooled analysis by HER2 and ER status.
Abstract No: 631 Poster Presentation
Clinical effects of prior anthracycline or taxane use
on eribulin as first-line treatment for HER+/- locally
recurrent or metastatic breast cancer (BC): results
Eribulin from 2 Phase 2, multicenter, single-arm studies.
Abstract No: 629 Poster Presentation
Clinical effects of prior trastuzumab on combination
eribulin mesylate + trastuzumab as first-line treatment
for HER2+ locally recurrent or metastatic breast cancer
(MBC): results from a phase 2, single-arm, multicenter
Eribulin study.
Abstract No: 635 Poster Presentation
Phase II feasibility study of dose-dense doxorubicin
and cyclophosphamide (AC) followed by eribulin mesylate
Eribulin with or without prophylactic growth factor (GF) for
adjuvant treatment of early-stage breast cancer (EBC)
Abstract No:
TPS670 Poster Presentation
Eribulin Phase I/IB trial of eribulin and everolimus in patients
with triple negative metastatic breast cancer (TNBC)
Abstract No:
TPS2637 Poster Presentation
Phase I/II trial of eribulin mesylate carboplatin and
trastuzumab (ECH) as neoadjuvant therapy for operable
Eribulin HER2 positive (HER2+) breast cancer
Abstract No: 604 Poster Presentation
A Phase II study of eribulin mesylate in combination
with trastuzumab and pertuzumab in patients (pts) with
Eribulin metastatic, human epidermal growth factor receptor
2-positive breast cancer
Abstract No:
TPS668 Poster Presentation
Eribulin
Phase II study of eribulin mesylate in patients with
Abstract No: advanced soft tissue sarcoma
10567 Poster Presentation
Time to progression and time to treatment failure in
patients with triple-negative metastatic breast cancer
Eribulin receiving eribulin mesylate in a community oncology
setting
Abstract No:
E12039 Publication Only
A Comparative Effectiveness Analysis of Single Agent
Eribulin Cytotoxics in Triple Negative Metastatic Breast Cancer
(TN-MBC) Patients
Abstract No:
E17648 Publication Only
Efficacy and toxicity profile of eribulin mesylate for
Eribulin metastatic breast cancer (MBC) patients (pts) in the
routine clinic: A French observational study
Abstract No:
E11555 Publication Only
Some of the information discussed in this release is about investigational uses for eribulin and an investigational product lenvatinib. Eribulin is indicated in Europe for the treatment of patients with locally advanced or MBC who have previously received at least two chemotherapeutic regimens. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.[1]
Notes to Editors
Eisai in Oncology
Our commitment to meaningful progress in oncology research, built on scientific expertise, is supported by a global capability to conduct discovery and preclinical research, and develop small molecules, therapeutic vaccines, and biologic and supportive care agents for cancer across multiple indications.
Halaven® (eribulin)
Eribulin is a non-taxane, microtubule dynamics inhibitor indicated for the treatment of people with breast cancer who have previously received at least two chemotherapeutic regimens for metastatic disease and whose prior therapy should have included an anthracycline and a taxane.[1] Eribulin belongs to a class of antineoplastic agents, the halichondrins, which are natural products, isolated from the marine sponge Halichondria okadai. It is believed to work by inhibiting the growth phase of microtubule dynamics which prevents cell division.
Lenvatinib (E7080)
Lenvatinib is an orally active, selective inhibitor of receptor tyrosine kinases (RTKs), including KDR (VEGFR-2), Flt-1 (VEGFR-1), FGFR1, PDGFR-β and c-kit involved in angiogenesis and tumour proliferation.[2],[3] It is currently under investigation as a treatment for thyroid, hepatocellular, endometrial and other solid tumour types. Eisai has initiated a global phase III trial with lenvatinib in hepatocellular carcinoma (HCC) and is conducting phase II studies of lenvatinib in several other tumour types.
About Eisai
Eisai is one of the world's leading research and development (R&D) based pharmaceutical companies and we define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care (hhc).
Eisai concentrates its R&D activities in three key areas:
- Oncology including: anticancer therapies; tumour regression, tumour suppression, antibodies, etc.
- Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight loss
- Vascular/Immunological reaction including: thrombocytopenia, rheumatoid arthritis, psoriasis, inflammatory bowel disease
With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 10,000 people worldwide. From its EMEA Knowledge Centre in Hatfield, UK, Eisai has recently expanded its business operations to include Europe, the Middle East, Africa, Russia and Oceania (EMEA). Eisai EMEA has sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Czech Republic, Slovakia, the Netherlands, Belgium, Luxembourg, Russia and the Middle East.
For further information please visit our web site http://www.eisai.co.uk
References
1. SPC Halaven (updated December 2013). Available at: http://www.medicines.org.uk/emc/medicine/24382. Last accessed May 2014
2. Matsui J, et al. Clin Cancer Res 2008;14:5459-65
3. Matsui J, et al. Int J Cancer 2008;122:664-71
Date of preparation: May 2014
Job code: Oncology-UK0015h
Share this article